Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of General Internal Medicine
Published in: Journal of General Internal Medicine 7/2013

01-07-2013 | Letters

Community-Acquired Pneumonia and Proton Pump Inhibitors

Authors: Matthew A. Rysavy, BS, Eric Ammann, MS, Ryan Carnahan, PharmD

Published in: Journal of General Internal Medicine | Issue 7/2013

Login to get access

Excerpt

To the Editors:—We read with interest the article by Jena and colleagues regarding the possibility of residual confounding in the association of proton pump inhibitors (PPIs) and community-acquired pneumonia (CAP).1 Specifically, we appreciated the argument for “falsification analysis,” which Jena has discussed elsewhere.2 …
Literature
1.
Jena AB, Sun E, Goldman DP. Confounding in the association of proton pump inhibitor use with risk of community-acquired pneumonia. JGIM. 2012;28(2):223–30.PubMedCrossRef
2.
Prasad V, Jena AB. Prespecified falsification end points: can they validate true observational associations? JAMA. 2013;309(3):241–2.PubMedCrossRef
3.
Weiss NS. Can the “specificity” of an association be rehabilitated as a basis for supporting a causal hypothesis? Epidemiology. 2002;13:6–8.PubMedCrossRef
4.
Rothman KJ, Greenland S. Causation and causal inference in epidemiology. Am J Public Health. 2005;95(S1):S144–50.PubMedCrossRef
5.
Giuliano C, Wilhelm SM, Kale-Pradhan PB. Are proton pump inhibitors associated with the development of community-acquired pneumonia? A meta-analysis. Expert Rev Clin Pharmacol. 2012;5(3):337–44.PubMedCrossRef
Metadata
Title
Community-Acquired Pneumonia and Proton Pump Inhibitors
Authors
Matthew A. Rysavy, BS
Eric Ammann, MS
Ryan Carnahan, PharmD
Publication date
01-07-2013
Publisher
Springer-Verlag
Published in
Journal of General Internal Medicine / Issue 7/2013
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-013-2432-2

Other articles of this Issue 7/2013

Journal of General Internal Medicine 7/2013 Go to the issue

Editorials and Comment

The Coming Golden Age of Disruptive Innovation in Health Care

Healing Arts: Materia Medica

Team Player

Clinical Practice: Clinical Vignettes

Diagnosis in Just Over a Minute: a Case of Chronic Eosinophilic Pneumonia

Comment

The Sticking Point: Diabetic Sharps Disposal Practices in the Community

Original Research

Depression and Risk of Hospitalizations for Ambulatory Care-Sensitive Conditions in Patients with Diabetes

Editorials

Medicare Part D Prescription Drug Program: Benefits, Unintended Consequences and Impact on Health Disparities
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits